AbbVie Inc
Health Care
Current price
Target price 00%
Ranks rating
76
Position in sub-industry
771 / 1361
Position in country
11036 / 14179
Return on Assets, %
3.5
-40.3
Net income margin, %
5.7
-180
EBITDA margin, %
39.9
-168.2
Debt to Equity, %
573.2
3.2
Intangible assets and goodwill, %
65.2
0.2
Revenue CAGR 3Y, %
5.8
12.5
Total Equity change 1Y, %
-40
-9
Revenue Y, % chg
-6.5
0
P/E
59.6
31
P/BV
27.6
1.8
P/S
5.2
10.3
EV/S
6.1
7.5
EV/EBITDA
13.1
-1.6
Average Analyst recommendation
Hold
Hold
Average upside forecasts, %
16.7
131.1
Forward P/E
14.1
21.4
Dividend Yield, %
3.7
1.1
Forward Dividend Yield, %
3.8
0.1
Expected dividend per share
6.2
0
Payout Ratio, %
220.8
0
Dividend Ex Date
2024-04-12
Competitors
Ranks
-
Vertex Pharmaceuticals Inc
00%
-
Regeneron Pharmaceuticals Inc
00%
-
Gilead Sciences Inc
00%
-
Biomarin Pharmaceutical Inc
00%
-
Seagen Inc
00%
-
Amgen Inc
00%
-
Moderna Inc
00%
-
Alnylam Pharmaceuticals Inc
00%
-
AbbVie Inc
00%
-
Biogen Inc
00%
Ready-made portfolio of the best Russian stocks
- Created by artificial intelligence
- Verified by analysts
- Available even to beginners
Company information
Country
United States of America
Sector
Health Care
Industry group
Pharmaceuticals, Biotechnology & Life Sciences
Industry
Biotechnology
Sub-sector
Health Care
Capitalization (millions of $)
287340.5
Ticker
ABBV.K
ISIN
US00287Y1091
IPO date
2013-01-02
Availability on Russian exchanges
Yes
Reporting for
2024-02-20
Date fact. publication of reports
2023-12-31
Company Description
AbbVie Inc. (AbbVie) is a research-based biopharmaceutical company. The Company is engaged in research and development, manufacturing, commercialization and sale of medicines and therapies. AbbVie offers its products in various therapeutic categories, including Immunology products, which include Humira, Skyrizi and Rinvoq; Oncology products consists of Imbruvica and Venclexta; Aesthetics products include Botox Cosmetic, Juvederm Collection and other aesthetics; Neuroscience products, such as Botox Therapeutic, Vraylar, Duopa and Duodopa, and Ubrelvy; Eye care products consists of Lumigan, Alphagan and Restasis ; Women's health products incudes Lo Loestrin, Orilissa and other women's health; and Other key products, which includes Mavyret, Creon, Lupron, Linzess and Synthroid. The Company's products are sold worldwide directly to wholesalers, distributors, government agencies, health care facilities and independent retailers from AbbVie-owned distribution centers and public warehouses.
A step towards better analytics
- find the best promotions through the Screener
- keep an eye on stock valuation
- download detailed reports
and much more after free registration
RegistrationMore convenient from your phone? Download: